Cargando…

Prevalence analysis of OX40-positive cell populations in solid tumors

Detalles Bibliográficos
Autores principales:	Ziai, James, Frantz, Gretchen, Zhang, Liping, Kozlowski, Cleopatra, Gilbert, Houston, Smith, Jacquelyn, Kowanetz, Marcin, Kim, Jeong M, Huseni, Mahrukh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645180/ http://dx.doi.org/10.1186/2051-1426-3-S2-P113

Ejemplares similares

A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
por: Ziai, James, et al.
Publicado: (2014)

Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer
por: Ziai, James, et al.
Publicado: (2015)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis
por: Ziai, James, et al.
Publicado: (2018)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Generation of direct antigen-sandwich enzyme-linked immune-sorbent assays (ELISA) for quantitation of HTLV-1 gp46, p24, Tax and related host cellular antigens OX40, OX40L and CD25
por: Tanaka, Reiko, et al.
Publicado: (2014)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
por: Liu, J, et al.
Publicado: (2009)

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine
por: Berrong, Zuzana, et al.
Publicado: (2014)

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
por: Akporiaye, Emmanuel T, et al.
Publicado: (2013)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort
por: Bossini-Castillo, L, et al.
Publicado: (2010)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand
por: Jiang, Hong, et al.
Publicado: (2015)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Finding the right balance: aOX40 immunotherapy enhances effector T cell function without impairing regulatory T cells intrinsic suppressive capacity in mouse tumor models
por: Moran, Amy, et al.
Publicado: (2015)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

Hepatitis B and hepatitis C prevalence in HIV positive pregnant women
por: Siame, Gilbert
Publicado: (2006)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?
por: Millican-Slater, R, et al.
Publicado: (2014)

P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
por: Kowanetz, M, et al.
Publicado: (2014)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_234i25e1ru6mpfpcoehk94u48p